Human germline gene therapy reconsidered.

This paper reevaluates the notion of human germline gene therapy (HGLGT) in light of developments in biomedicine, biotechnology, and ethical and policy analysis. The essay makes the following key points. First, because the distinction among "therapy," "prevention," and "enhancement" is not clear in human genetics, "gene therapy" is an inadequate descriptor of the process and goals of germline genetic alterations. The alternate use of the phrase "human germline genome modification" (HGLGM) could avoid a misleading label. Second, procedures that could be construed as genetic "enhancement" may not be as morally problematic as some have supposed, once one understands that the boundaries between therapy, prevention, and enhancement are not obvious in genetic medicine. Third, HGLGM might be the medically and morally most appropriate way of avoiding the birth of a child with a genetic disease in only a small range of cases. Fourth, there are still many ethical and scientific problems relating to the safety and efficacy of HGLGM.

[1]  G. Mcgee.  The Perfect Baby , 2019, Nature Medicine.

[2]  P. Klatt,et al.  'Super p53' mice exhibit enhanced DNA damage response, are tumor resistant and age normally , 2002, The EMBO journal.

[3]  J. Cohen,et al.  Mitochondria in human offspring derived from ooplasmic transplantation. , 2001, Human reproduction.

[4]  H. Willard.  Artificial Chromosomes Coming to Life , 2000, Science.

[5]  D. Turnbull,et al.  The inheritance of mitochondrial DNA heteroplasmy: random drift, selection or both? , 2000, Trends in genetics : TIG.

[6]  S. Willadsen,et al.  Mitochondrial DNA heteroplasmy after human ooplasmic transplantation. , 2000, Fertility and sterility.

[7]  D. Resnik.  The Moral Significance of the Therapy-Enhancement Distinction in Human Genetics , 2000, Cambridge Quarterly of Healthcare Ethics.

[8]  S. Willadsen,et al.  Spontaneous and artificial changes in human ooplasmic mitochondria. , 2000, Human reproduction.

[9]  P. Lansdorp,et al.  Extension of cell life-span and telomere length in animals cloned from senescent somatic cells. , 2000, Science.

[10]  Dan W. Brock,et al.  From Chance to Choice: Genetics and Justice , 2000 .

[11]  R. Kumar,et al.  A plausible mechanism for gene correction by chimeric oligonucleotides. , 2000, Biochemistry.

[12]  J. Tilly,et al.  Reproductive biology: Mitochondria and the death of oocytes , 2000, Nature.

[13]  H. Miller.  Gene Therapy on Trial , 2000, Science.

[14]  E Marshall,et al.  Gene Therapy Death Prompts Review of Adenovirus Vector , 1999, Science.

[15]  W. Anderson,et al.  Prospects for in utero human gene therapy. , 1999, Science.

[16]  Z. Rosenwaks,et al.  A reliable technique of nuclear transplantation for immature mammalian oocytes. , 1999, Human reproduction.

[17]  J. Grifo,et al.  In vitro maturation of human preovulatory oocytes reconstructed by germinal vesicle transfer. , 1999, Fertility and sterility.

[18]  J W Gordon,et al.  Genetic Enhancement in Humans , 1999, Science.

[19]  P. J. Langer.  Human Germline Gene Therapy: Scientific, Moral and Political Issues , 1999 .

[20]  D. Wolf,et al.  Nuclear transfer in the rhesus monkey: practical and basic implications. , 1999, Biology of reproduction.

[21]  F. Collins,et al.  New goals for the U.S. Human Genome Project: 1998-2003. , 1998, Science.

[22]  J. Sinclair,et al.  Mitochondrial transfer between oocytes: potential applications of mitochondrial donation and the issue of heteroplasmy. , 1998, Human reproduction.

[23]  J. van Blerkom,et al.  DNA strand breaks and phosphatidylserine redistribution in newly ovulated and cultured mouse and human oocytes: occurrence and relationship to apoptosis. , 1998, Human reproduction.

[24]  T. Schimmel,et al.  Ooplasmic transfer in mature human oocytes. , 1998, Molecular human reproduction.

[25]  A. Bonnicksen.  Transplanting Nuclei between Human Eggs: Implications for Germ-Line Genetics , 1998, Politics and the Life Sciences.

[26]  U. Schuklenk.  Who's Afraid of Human Cloning? , 1998 .

[27]  E. Parens.  Is better always good? The Enhancement Project. , 1998, The Hastings Center report.

[28]  C. Strom,et al.  Preimplantation diagnosis of single gene disorders by two-step oocyte genetic analysis using first and second polar body. , 1997, Biochemical and molecular medicine.

[29]  T. Schimmel,et al.  Birth of infant after transfer of anucleate donor oocyte cytoplasm into recipient eggs , 1997, The Lancet.

[30]  T Friedmann,et al.  Overcoming the obstacles to gene therapy. , 1997, Scientific American.

[31]  E. Juengst,et al.  Can enhancement be distinguished from prevention in genetic medicine? , 1997, The Journal of medicine and philosophy.

[32]  N. Holtug.  Altering Humans—The Case For and Against Human Gene Therapy , 1997, Cambridge Quarterly of Healthcare Ethics.

[33]  I. Wilmut,et al.  "Viable Offspring Derived from Fetal and Adult Mammalian Cells" (1997), by Ian Wilmut et al. , 2014 .

[34]  E. Parens.  Taking behavioral genetics seriously. , 1996, The Hastings Center report.

[35]  Richard A. Posner,et al.  Aging and old age , 1996 .

[36]  E. Juengst,et al.  "Prevention" and the goals of genetic medicine. , 1995, Human gene therapy.

[37]  S. Sawyer.  Reproductive health in young people with cystic fibrosis. , 1995, Current opinion in pediatrics.

[38]  E. Schon,et al.  Germ-Line Therapy to Cure Mitochondrial Disease: Protocol and Ethics of In Vitro Ovum Nuclear Transplantation , 1995, Cambridge Quarterly of Healthcare Ethics.

[39]  W. F. Anderson.  Genetic engineering and our humanness. , 1994, Human gene therapy.

[40]  M. Capecchi,et al.  Targeted gene replacement. , 1994, Scientific American.

[41]  D. Resnik.  Debunking the slippery slope argument against human germ-line gene therapy. , 1994, Journal of Medicine and Philosophy.

[42]  N. Wivel,et al.  Germ-line gene modification and disease prevention: some medical and ethical perspectives. , 1993, Science.

[43]  M. Sawicki,et al.  Human Genome Project. , 1993, American journal of surgery.

[44]  B. Davis.  Germ-line therapy: evolutionary and moral considerations. , 1992, Human gene therapy.

[45]  R. Munson,et al.  Germ-Line Gene Therapy and the Medical Imperative , 1992, Kennedy Institute of Ethics journal.

[46]  W. Anderson,et al.  Germ-Line Gene Therapy: A New Stage of Debate , 1992, Law, medicine & health care : a publication of the American Society of Law & Medicine.

[47]  B. K. Zimmerman,et al.  Human germ-line therapy: the case for its development and use. , 1991, The Journal of medicine and philosophy.

[48]  E. Berger,et al.  Genetic disorders and the ethical status of germ-line gene therapy. , 1991, The Journal of medicine and philosophy.

[49]  W. Anderson,et al.  Human gene therapy: why draw a line? , 1989, The Journal of medicine and philosophy.

[50]  E. Juengst,et al.  Germ-line gene therapy and the clinical ethos of medical genetics , 1989, Theoretical medicine.

[51]  Anderson Wf.  Human gene therapy: scientific and ethical considerations. , 1985 .

[52]  A. Wolffe,et al.  Reprogramming nuclei: insights from cloning, nuclear transfer and heterokaryons. , 2000, Journal of cell science.

[53]  M. Bacchetta,et al.  Interventions in the human genome: some moral and ethical considerations. , 1998, The Journal of medicine and philosophy.

[54]  M. Mehlman,et al.  Access to the Genome: The Challenge to Equality , 1998 .

[55]  B. Gill,et al.  Engineering the Genome , 1998 .

[56]  D. Resnik.  Genetic engineering and social justice: a Rawlsian approach. , 1997, Social theory and practice.

[57]  J. A. Robertson.  Children of choice , 1994 .

[58]  L Walters,et al.  Human gene therapy: ethics and public policy. , 1991, Human gene therapy.

[59]  L. Walters.  The ethics of human gene therapy , 1986, Nature.